Progress in the application of omalizumab in the treatment of chronic inducible urticaria
CHEN Ziyan
ZOU Hui
LIN Tianyi
WU Weihong
CHEN Jiaoquan
LIANG Bihua
LI Runxiang
LI Huaping
ZHU Huilan
Abstract：Chronic inducible urticaria(CIndU)is a chronic urticaria caused by unique trig-gers,manifested by wheals and angioedema as common symptoms.Omalizumab is a recombinant humanized anti-IgE antibody,which is currently listed as the third-line treatment for CIndU in in-ternational guidelines,and there are some precedents for the treatment of CIndU with omalizumab,but the relevant dose,efficacy,adverse reactions and other data are relatively insufficient.The purpose of this article is to review the efficacy and treatment progress of omalizumab in the treat-ment of various types of CIndU,and to provide a rationale for the treatment of patients with CIndU.
Keywords：omalizumabchronic inducible urticariadermographiacold contact urticariacholinergic urticariadelayed-pressure urticaria
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 858-864 )